目的:探讨血清β2-微球蛋白(β2-MG)、内脏脂肪素(visfatin)水平变化与老年高血压患者血压变异性(BPV)的关联性。方法:选取某院2021年1月—2022年12月收治的120例老年高血压患者为研究组,同期120例血压正常体检老年人为对照组,根据24 h...目的:探讨血清β2-微球蛋白(β2-MG)、内脏脂肪素(visfatin)水平变化与老年高血压患者血压变异性(BPV)的关联性。方法:选取某院2021年1月—2022年12月收治的120例老年高血压患者为研究组,同期120例血压正常体检老年人为对照组,根据24 h收缩压变异性(24 h SBPV)将研究组分为低BPV(35例,24 h SBPV<15%)、中BPV(47例,24 h SBPV为15%~20%)、高BPV(38例,24 h SBPV>20%)3个亚组。比较2组入院时血清β2-MG、visfatin水平、血压参数,分析入院时血清β2-MG、visfatin水平与血压参数的相关性,比较不同程度BPV患者入院时血清β2-MG、visfatin水平,分析入院时血清β2-MG、visfatin联合检测对老年高血压患者BPV程度的诊断价值。结果:研究组β2-MG[(5.46±1.13)mg/mL]、visfatin[(9.75±2.08)μg/L]水平高于对照组[(1.37±0.42)mg/mL、(2.86±0.61)μg/L],差异具有统计学意义(P<0.05);研究组24 h DBP、24 h SBP、24 h DBPV、24 h SBPV均高于对照组,差异具有统计学意义(P<0.05);入院时血清β2-MG、visfatin水平与24 h DBP、24 h SBP、24 h DBPV、24 h SBPV均呈正相关,差异具有统计学意义(r_(β2-MG)=0.516、0.622、0.439、0.725,r_(visfatin)=0.703、0.681、0.617、0.658)(P<0.05);不同程度BPV患者入院时血清β2-MG、visfatin水平比较:高BPV>中BPV>低BPV,差异具有统计学意义(P<0.05);入院时,血清β2-MG、visfatin联合鉴别诊断高BPV严重程度AUC为0.909,大于单独指标鉴别诊断,差异具有统计学意义(P<0.05)。结论:β2-MG、visfatin水平变化与老年高血压患者血压变异性有密切关联,可作为临床诊断病情的重要参考依据。展开更多
The role of beta2-microglobulin(β2M) in dialysisrelated amyloidosis as a specific amyloid precursor was defined in the 1980 s. Studies in those years were largely related to β2M amyloidosis. In 2005, for what was pr...The role of beta2-microglobulin(β2M) in dialysisrelated amyloidosis as a specific amyloid precursor was defined in the 1980 s. Studies in those years were largely related to β2M amyloidosis. In 2005, for what was probably the first time in the available literature, we provided data about the association betweenβ2M and early-onset atherosclerosis in hemodialysis patients without co-morbidities. In recent years, the role of uremic toxins in uremic atherosclerosis and the interest in β2M as a marker of cardiovascular(CV) and/or mortality risk have grown. In the current literature,clinical studies suggest that β2M is an independent, significant predictor of mortality, not only in dialysis patients, but also in predialysis patients and in the highrisk portion of the general population, and it seems to be a factor strongly linked to the presence and severity of CV disease. It is still unknown whether β2M is only a uremic toxin marker or if it also has an active role in vascular damage, but data support that it may reflect an increased burden of systemic atherosclerosis in a setting of underlying chronic kidney disease. Thus, although there have been some inconsistencies among the various analyses relating to β2M, it promises to be a novel risk marker of kidney function in the awareness and detection of high-risk patients. However, more research is required to establish the pathophysiological relationships between retained uremic toxins and further biochemical modifications in the uremic milieu to get answers to the questions of why and how. In this review, the recent literature about the changing role of β2M in uremic patients will be examined.展开更多
文摘目的:探讨血清β2-微球蛋白(β2-MG)、内脏脂肪素(visfatin)水平变化与老年高血压患者血压变异性(BPV)的关联性。方法:选取某院2021年1月—2022年12月收治的120例老年高血压患者为研究组,同期120例血压正常体检老年人为对照组,根据24 h收缩压变异性(24 h SBPV)将研究组分为低BPV(35例,24 h SBPV<15%)、中BPV(47例,24 h SBPV为15%~20%)、高BPV(38例,24 h SBPV>20%)3个亚组。比较2组入院时血清β2-MG、visfatin水平、血压参数,分析入院时血清β2-MG、visfatin水平与血压参数的相关性,比较不同程度BPV患者入院时血清β2-MG、visfatin水平,分析入院时血清β2-MG、visfatin联合检测对老年高血压患者BPV程度的诊断价值。结果:研究组β2-MG[(5.46±1.13)mg/mL]、visfatin[(9.75±2.08)μg/L]水平高于对照组[(1.37±0.42)mg/mL、(2.86±0.61)μg/L],差异具有统计学意义(P<0.05);研究组24 h DBP、24 h SBP、24 h DBPV、24 h SBPV均高于对照组,差异具有统计学意义(P<0.05);入院时血清β2-MG、visfatin水平与24 h DBP、24 h SBP、24 h DBPV、24 h SBPV均呈正相关,差异具有统计学意义(r_(β2-MG)=0.516、0.622、0.439、0.725,r_(visfatin)=0.703、0.681、0.617、0.658)(P<0.05);不同程度BPV患者入院时血清β2-MG、visfatin水平比较:高BPV>中BPV>低BPV,差异具有统计学意义(P<0.05);入院时,血清β2-MG、visfatin联合鉴别诊断高BPV严重程度AUC为0.909,大于单独指标鉴别诊断,差异具有统计学意义(P<0.05)。结论:β2-MG、visfatin水平变化与老年高血压患者血压变异性有密切关联,可作为临床诊断病情的重要参考依据。
文摘The role of beta2-microglobulin(β2M) in dialysisrelated amyloidosis as a specific amyloid precursor was defined in the 1980 s. Studies in those years were largely related to β2M amyloidosis. In 2005, for what was probably the first time in the available literature, we provided data about the association betweenβ2M and early-onset atherosclerosis in hemodialysis patients without co-morbidities. In recent years, the role of uremic toxins in uremic atherosclerosis and the interest in β2M as a marker of cardiovascular(CV) and/or mortality risk have grown. In the current literature,clinical studies suggest that β2M is an independent, significant predictor of mortality, not only in dialysis patients, but also in predialysis patients and in the highrisk portion of the general population, and it seems to be a factor strongly linked to the presence and severity of CV disease. It is still unknown whether β2M is only a uremic toxin marker or if it also has an active role in vascular damage, but data support that it may reflect an increased burden of systemic atherosclerosis in a setting of underlying chronic kidney disease. Thus, although there have been some inconsistencies among the various analyses relating to β2M, it promises to be a novel risk marker of kidney function in the awareness and detection of high-risk patients. However, more research is required to establish the pathophysiological relationships between retained uremic toxins and further biochemical modifications in the uremic milieu to get answers to the questions of why and how. In this review, the recent literature about the changing role of β2M in uremic patients will be examined.
